|
Gene: RPP21 |
Gene summary for RPP21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPP21 | Gene ID | 79897 |
Gene name | ribonuclease P/MRP subunit p21 | |
Gene Alias | C6orf135 | |
Cytomap | 6p22.1 | |
Gene Type | protein-coding | GO ID | GO:0000966 | UniProtAcc | A0A1U9X8H3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79897 | RPP21 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.29e-05 | 1.32e-01 | 0.0155 |
79897 | RPP21 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.70e-09 | 3.39e-01 | -0.1808 |
79897 | RPP21 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.59e-07 | 2.86e-01 | -0.0811 |
79897 | RPP21 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.53e-03 | 1.36e-01 | -0.1088 |
79897 | RPP21 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.18e-10 | 2.30e-01 | -0.1954 |
79897 | RPP21 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.01e-04 | 2.92e-01 | -0.2602 |
79897 | RPP21 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.90e-02 | 2.43e-01 | -0.2196 |
79897 | RPP21 | HTA11_3361_2000001011 | Human | Colorectum | AD | 7.91e-05 | 1.90e-01 | -0.1207 |
79897 | RPP21 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.23e-03 | 1.62e-01 | -0.1526 |
79897 | RPP21 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.44e-12 | 2.49e-01 | -0.1464 |
79897 | RPP21 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.32e-10 | 2.23e-01 | -0.1001 |
79897 | RPP21 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.17e-15 | 4.19e-01 | -0.059 |
79897 | RPP21 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.52e-06 | 2.57e-01 | -0.2061 |
79897 | RPP21 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.83e-05 | 2.44e-01 | -0.0842 |
79897 | RPP21 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.96e-03 | 2.15e-01 | -0.0179 |
79897 | RPP21 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.40e-16 | 3.44e-01 | 0.096 |
79897 | RPP21 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.40e-03 | 2.21e-01 | 0.0446 |
79897 | RPP21 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.13e-05 | 3.06e-01 | 0.0528 |
79897 | RPP21 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.76e-07 | 3.33e-01 | 0.0131 |
79897 | RPP21 | HTA11_10623_2000001011 | Human | Colorectum | AD | 8.98e-03 | 1.86e-01 | -0.0177 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | |
Lung | IAC | |
Lung | AIS | |
Lung | AAH | |
Lung | MIAC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034470 | Colorectum | MSI-H | ncRNA processing | 48/1319 | 395/18723 | 1.54e-04 | 4.47e-03 | 48 |
GO:0034660 | Colorectum | MSI-H | ncRNA metabolic process | 53/1319 | 485/18723 | 9.66e-04 | 1.68e-02 | 53 |
GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:00905023 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
GO:00344713 | Esophagus | ESCC | ncRNA 5'-end processing | 18/8552 | 21/18723 | 1.81e-04 | 1.16e-03 | 18 |
GO:00009663 | Esophagus | ESCC | RNA 5'-end processing | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
GO:00991163 | Esophagus | ESCC | tRNA 5'-end processing | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
GO:00016823 | Esophagus | ESCC | tRNA 5'-leader removal | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00905011 | Liver | HCC | RNA phosphodiester bond hydrolysis | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPP21 | SNV | Missense_Mutation | novel | c.212N>A | p.Arg71Gln | p.R71Q | Q9H633 | protein_coding | deleterious(0.01) | possibly_damaging(0.889) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
RPP21 | insertion | Frame_Shift_Ins | novel | c.471_472insAGAAACAGAATTA | p.Gly158ArgfsTer8 | p.G158Rfs*8 | Q9H633 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
RPP21 | SNV | Missense_Mutation | rs866719394 | c.257N>A | p.Arg86His | p.R86H | Q9H633 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPP21 | SNV | Missense_Mutation | rs762968053 | c.442C>T | p.Arg148Cys | p.R148C | Q9H633 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RPP21 | SNV | Missense_Mutation | c.122C>T | p.Thr41Ile | p.T41I | Q9H633 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
RPP21 | SNV | Missense_Mutation | rs539399498 | c.280C>T | p.Arg94Cys | p.R94C | Q9H633 | protein_coding | tolerated(0.05) | probably_damaging(0.976) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPP21 | SNV | Missense_Mutation | rs148620646 | c.289N>A | p.Val97Ile | p.V97I | Q9H633 | protein_coding | tolerated(0.18) | probably_damaging(0.968) | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPP21 | SNV | Missense_Mutation | novel | c.446N>G | p.Leu149Arg | p.L149R | Q9H633 | protein_coding | tolerated_low_confidence(0.08) | benign(0.013) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPP21 | SNV | Missense_Mutation | novel | c.124G>A | p.Glu42Lys | p.E42K | Q9H633 | protein_coding | tolerated(0.26) | possibly_damaging(0.779) | TCGA-P3-A5Q5-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RPP21 | SNV | Missense_Mutation | rs754998113 | c.313N>T | p.Arg105Cys | p.R105C | Q9H633 | protein_coding | tolerated(0.1) | probably_damaging(0.98) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |